BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

Terrence X. O'Brien, MD, MS, FACC	POSITION TITLE Professor of Medicine and Cell Biology and Anatomy
eRA COMMONS USER NAME OBRIENTE	

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Stanford University, Palo Alto, CA	B.S.	1980	Chemistry and Biology
Stanford University, Palo Alto, CA	M.S.	1980	Biology
University of California, San Diego, CA	M.D.	1984	Medicine
University of Texas Southwestern Medical Center,	Residency	1984-1987	Internal Medicine
University of California, San Diego, CA	Clinical Fellow	1988-1990	Clinical Cardiology
University of California, San Diego, CA	Research	1990-1993	Molecular Cardiology

A. Positions and Honors

Positions and Employment

1987-1988 Clinical Assistant Professor of Medicine, University of Texas Southwestern, Dallas, Texas
1990-1992 Instructor in Medicine; University of California Medical Center San Diego, California
1990-1993 Associate Investigator; Veterans Administration Medical Center, San Diego, California
1991-1993 Research Fellowship, Molecular Biology, Bugher Foundation, American Heart Association
1992-1993 Clinical Assistant Professor of Medicine, University of California, San Diego, CA
1993-2000 Assistant Professor of Medicine and Cell Biology and Anatomy, MUSC, Charleston, SC
1993-On Staff Physician-Cardiology, RHJ-VAMC, Charleston, SC
1995-On Director, Echocardiography Laboratory, RHJ-VAMC, Charleston, SC
1998-On Faculty, Molecular & Cellular Biology & Pathobiology Program, MUSC, Charleston, SC
2000-2007 Associate Professor of Medicine and Cell Biology and Anatomy, MUSC, Charleston, SC
2001-On Medical Director, MUSC Cardiology at East Cooper (Outreach Clinic)
2003-On Director, Cardiovascular Clinical Research, MUSC, Charleston, SC
2007-On Professor of Medicine (Cardiology) and Cell Biology and Anatomy, MUSC, Charleston, SC

Other Experience and Professional Memberships

Honors

1976-1980 Stanford University Four-Year Academic Undergraduate Scholarship
1977-1980 California State Academic Scholarship, Stanford University
1980-1984 Regents Scholarship, University of California, San Diego, School of Medicine
1992 Trainee Investigator Award for Research, American Federation for Clinical Research
1990-1993 Associate Investigator Career Development Award, Veterans Administration
1991-1993 Bugher Fellowship in Molecular Biology, American Heart Association
1995-1999 Research Associate Award, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC
1999 Young Investigator Award, American Heart Association Conference, Salt Lake City, Utah
2001-On Tenure, Medical University of South Carolina
2006 Golden Apple Teaching Award Nomination, AMSA, MUSC
2005-2008 Member, VA Merit Review Cardiology Study Section (Chair 2007-8)
2006-On Member, Charleston Research Institute Board of Directors
2006-On Associate Editor, Cardiology Section, American Journal of the Medical Sciences

2007-2008 Awarded "Best Doctors in America" peer recognition.

Memberships: American Heart Association, American College of Cardiology, Heart Failure Society of America, American Society of Echocardiography, International Heart Research Society, American Medical Association

B. Selected Publications (as of 8/1/08) (of a total of 46) (in chronological order)

1. Ross RS and O'Brien TX. The mouse that roared: Cardiovascular applications of transgenic technology. *Heart Fai*lure, 8: 109-120, 1992.
2. Lee KJ, Ross RS, Rockman HA, Harris AN, O'Brien TX, Van Bilsen M, Shubeita HE, Kandol R, Brem G, Price J, Evans SM, Zhu H, Franz WM, Chien KR. Myosin light chain-2-luciferase transgenic mice reveal distinct regulatory programs for cardiac and skeletal muscle specific expression of a single contractile protein gene. *J Bio Chem*, 267: 15875-15885, 1992.
3. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, Van-Bilsen M, O'Brien TX, Evans SM. Transcriptional regulation during cardiac growth and development. *Ann Rev Physio*, 55: 77-95, 1993.
4. O'Brien TX, Lee K., Chien KR. Positional specification of the ventricular myosin light chain-2 gene in the primitive murine heart tube. *Proc Natl Acad Sci USA*, 90:5157-5161, 1993.
5. Evans SM and O'Brien TX. Expression of the helix-loop-helix factor Id during mouse embryonic development. *Dev Biol*, 159: 485-499, 1993.
6. Chien KR, Knowlton KU, Lee KJ, Ross RS, Rockman HA, O'Brien TX. Molecular analysis of cardiac growth and development in transgenic mouse model systems. In: Idiopathic Dilated Cardiomyopathy, Figulla et al. (Eds.), Springer-Verlag Berlin Heidelberg, 1993.
7. Kubalak SW, Miller-Hance WC, O'Brien TX, Dyson, Chien KR. Chamber specification of atrial myosin light chain-2 expression precedes septation during murine cardiogenesis. *J Bio Chem*, 269:16961-70, 1994.
8. Thompson JT, Rackley MS, and O'Brien TX. Up-regulation of the cardiac homeobox gene Nkx2.5 (CSX) in feline right ventricular pressure overload. *Am J Physiol* 274: H1569-H1573, 1998.
9. O'Brien TX, Schuyler GT, Rackley, MS, Thompson JT. F1-ATP synthase β-subunit and cytochrome *c* transcriptional regulation in right ventricular hemodynamic overload and hypertrophically stimulated cardiocytes. *J Mol Cell Card.* 31:167-178, 1999.
10. Gramling-Babb, P and O'Brien, TX: Recent advances in dobutamine stress echocardiography. *Clin Cardiol* 23: 560-570, 2000.
11. Brown AM and O'Brien TX. Upcoming therapies for congestive heart failure. *Clinical Cornerstones,* 3: 36-44, 2000.
12. Thompson JT and O'Brien TX. Cardiovascular Genetic Diseases. In: Taylor GJ, ed. *Primary Care Management of Heart Disease*, Mosby, p. 481-488, 2000.
13. Paul SC and O'Brien TX. Chest x-ray and vascular studies. In: Taylor, GJ, ed. *Primary Care Management of Heart Disease*. Mosby, pp. 77-84, 2000.
14. Mitchell, GF, Tardif, JC, Arnold, JMO, Marchiori, G, O'Brien, TX, Dunlap, MA, Pfeffer, MA: Pulsatile Hemodynamics in Congestive Heart Failure. *Hypertension*, 38:1433-1439, 2001.
15. Muller JG, Thompson JT, Rackley MS, McQuinn TC, Menick DR, O'Brien TX. Co-regulation of Nkx2-5 and serum response factor induced activation of the cardiac sodium-calcium exchanger promoter. *J Mol Cell Card,* 34:807-821, 2002.
16. Harris BS, O'Brien TX, Gourdie RG. Coronary arteriogenesis and differentiation of periarteriolar Purkinje fibers in chick: Is there a link? *Texas Heart Journal*, 29:262-270, 2002.
17. Gourdie RG, Harris BS, Bond J, O'Brien TX, Mikawa T, Sedmera D, Thompson RP. His-Purkinje lineages and development. In: Development of the cardiac conduction system. John Wiley and Sons. *Novartis Symposia Series 250.* 122-134, 2003.

18. Gourdie RG, Harris BS, Bond J, Justus C, Hewett K, O'Brien TX, Thompson RP, Sedmera D. Development of the cardiac pacemaking and conduction system. *Birth Defects Research*, 69:46-57, 2003.
19. Teunissen BE, Jansen AT, van Amersfoorth SC, O'Brien TX, Jongsma HJ, Bierhuizen MF. Analysis of the rat connexin 43 promoter in neonatal cardiomyocytes. *Gene*, 322:123-36, 2003.
20. Jay PY, Harris BS, Maguire CT, Buerger A, Wakimoto H, Tanaka M, Kupershmidt S, Roden DM, Schultheiss TM, O'Brien TX, Gourdie RG, Berul CI, Izumo Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. *J Clin Invest*. 113:1130-7, 2004.
21. Gourdie RG, Kubalak SW, O'Brien TX, Chien KR, Mikawa T. Development of Pacemaking and Cardiac Conduction System Lineages. In: Molecular Basis of Cardiovascular Disease, 2nd Edition, (ed. KR Chien), W. B. Saunders, p225-237, 2004.
22. Jay PY, Harris BS, Buerger A, Rozhitskaya O, Maguire CT, Barbosky L, McCusty E, Berul CI, O'Brien TX, Gourdie RG, Izumo S. Function follows form: Cardiac conduction system defects in Nkx2.5 mutation. *Anatomical Record*, 280A:966-972,2004.
23. Harris BS, Jay PY, Rackley MS, Izumo S, O'Brien TX, Gourdie RG. Transcriptional regulation of cardiac conduction system. *Anatomical Record*, 280A:1036-1045,2004.
24. O'Brien, TX, Smith, DA. Congestive Heart Failure Overview. In: Emedicine Consumer Health. Emedicine, Inc., St. Petersburg, Fl, (www.emedicinehealth.com/Articles/10929-1.asp). January 7, 2005.
25. Harris BS, Gourdie RG, O'Brien TX. The atrioventricular conduction system and transcription factors Nkx2.5 and Msx2. Editorial, *Journal of Cardiovascular Electrophysiology*, 16:86-87, 2005.
26. Little WC, Zile M, Kitzman DW, Hundley WG, O'Brien TX, deGroof RC. The effects of Alagebrium Chloride ALT-711, a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. *Journal of Cardiac Failure*, 11:191-195, 2005.
27. Mitchell GF, Arnold MO, Dunlap ME, O'Brien TX, Marchiori G, Warner E, Granger CB, Desai S, Pfeffer MA. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The Charm Trial. *European J. of Heart Failure*, 8:191-7, 2005.
28. Harris BS, Spruill L, Edmonson AM, Rackley MS, Benson DW, *O'Brien TX, *Gourdie RG (*=co-senior authors). Differentiation of cardiac Purkinje fibers requires precise spatiotemporal regulation of Nkx2-5 expression. *Developmental Dynamics.* 235:38-49, 2006.
29. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien TX, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. *Journal of the American College of Cardiology*, 49:2151-2159, 2007.
30. Sidney DS, O'Brien TX. Pericarditis, constrictive. (www.emedicine.com) *eMedicine* Journal>Medicine>Cardiology, Vol. 9, July 5, 2008.
31. Bonnema DD, O'Brien TX, Pericarditis constrictive-effusive. (www.emedicine.com) *eMedicine* Journal>Medicine>Cardiology, Vol. 9, July 26, 2008.
32. O'Brien TX and Epps AR. Cardiovascular risk in women with high normal blood pressure. (editorial) *Southern Med. J*., In press, 2008.

C. Research Support

Ongoing Research

Dept. of Veterans Affairs Merit Award: Role-PI, 4/1/06-3/31/09. The cardiac conduction system and Nkx2-5. $375,000/3 years.

NIH-NHLBI: Role-site PI, 6/01/08-Initiation. Clinical Trial at the RHJ-VAMC and MUSC. Treatmetn of preserved cardiac function heart failure with an aldosterone antagonist. The TOPCAT trial.

Cardiokine Biopharma: Role-site PI, 5/01/08-Initiation: Clinical Trial at the RHJ-VAMC. Treatment of hyponatremia based on lixivaptan in NYHA Class III/IV cardiac failure. The BALANCE trial.

Amgen: Role-Site PI, 02/01/08-Initiation. Clinical Trial at the RHJ-VAMC. A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of darbepoetin alfa treatment on mortality and morbidity in heart failure subjects with symptomatic left ventricular systolic dysfunction and anemia. The RED-HF trial.

Encysive Pharmaceuticals: Role-Site PI, 05/01/06-Initiation. Clinical Trial at the RHJ-VAMC and MUSC: Sitaxsentan sodium to improve exercise tolerance in subjects with diastolic heart failure.

Completed Research (Last Three Years)

NIH/NHLBI-PO1 HL48788-11 (G. Cooper -PI) 08/01/93-07/30/08. Program Project Grant: Load-Induced Cardiac Hypertrophy in the Adult Mammal. Role: PI Core E. Morphology and molecular imaging core. $32,478/year.

CV Therapeutics: Role-Site PI, 3/22/05–5/1/07. MERLIN-TIMI 36: A randomized, double-blind, parallel group, placebo-controlled, multinational, clinical trial to evaluate the efficacy and safety of ranolazine versus placebo in patients with non-ST segment elevation acute coronary syndromes. $23,300.

Amylin Pharmaceuticals: Role-Site PI, 2/1/05-2/1/07. A Phase 2, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure.

Dept. of Veterans Affairs Cooperative Study 526; Role: Site PI, 8/1/04-7/1/07. DITPA, a thyroid analogue to treat heart failure: Phase II trial.

Otsuka America; Role: Site PI, 11/11/03-9/30/06: EVEREST/Clinical Trial: Multicenter, randomized, double-blind, placebo controlled study to evaluate the long-term efficacy and Safety of oral Tolvaptan tablets in subjects hospitalized with worsening congestive heart failure. $117,600.

PO1 HD039946-04 Gourdie (PI): 05/01/01-04/31/06.NIH/NICHD; Role: Co-PI. Program Project Grant: Patterning by invasive mesenchyme in the embryonic heart. Co-PI Project 1: The genetic origin of structural and functional defects of atrioventricular conduction in humans (PI-W. Benson).

VA Merit Award; Role: PI, 10/1/02-9/30/05, VA Research and Development: $389,000/3 years.

Otsuka America Pharmaceuticals; Role: Site PI, 08/01/02-8/1/05: METEOR/Clinical Trial: A multicenter, randomized, double-blind, placebo-controlled, efficacy study on the effects of Tolvaptan on LV dilatation and function in patients with HF and LV systolic dysfunction.

Pfizer Pharmaceuticals; Role: Site PI, 5/1/04 – 5/1/06: A randomized, double-blind, multi-center study evaluating the effects of Eplerenone versus placebo on ventricular remodeling in patients with left ventricular systolic dysfunction (EF<35%) and mild to moderate heart failure. $22,575.

Fujisawa Healthcare; Role: Site PI, 01/01/04-3/1/06: Phase 2, dose escalation evaluation of the pharmacokinetic and hemodynamic effects of carperitide in subjects with congestive heart failure.

Bristol Myers Squibb and Sanofi-Synthelabo; Role: Site PI, 05/01/02-12/1/06: I-PRESERVE/Clinical Trial. Irbesartan in heart failure with preserved systolic function. $66,520.